ArticleFrontiers in microbiology2026
Systematic characterization of SARS-CoV-2 spike protein subunit trafficking and secretion reveals enhanced strategies for vaccine design and quantification.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the widespread deployment of current COVID-19 vaccines, significant gaps remain in understanding the complete biological behavior of the SARS-CoV-2 spike (S) protein. Through systematic characterization of mammalian expression systems, this study shows that the full-length S protein exhibits a complex intracellular distribution, predominantly localizing not only to the cell membrane but also to the cytoplasm, nucleus, and extracellular compartments. Comparative analyses revealed distinct subunit-specific trafficking patterns. The S1 subunit showed increased intracellular accumulation and secretion compared to the full-length S protein, although with reduced surface expression. Conversely, the receptor-binding domain (RBD) and S2 domains were mainly associated with cytoskeletal (CS) structures. Notably, the signal sequence-enhanced RBD (SS-RBD) construct engineered in this study demonstrated dramatically enhanced extracellular accumulation, approximately 100-fold higher than the full-length S protein and 10-fold greater than S1, as measured by proximity extension assay (PEA). Signal peptide modification effectively redirected RBD from CS retention to efficient secretion, significantly improving detection sensitivity. PEA outperformed conventional methods such as flow cytometry (FACS), Western blotting (WB), and immunofluorescence, offering sensitivities several orders of magnitude higher. Consequently, these findings provide: (1) a structural framework for rational antigen design by distinguishing essential versus dispensable domains; (2) experimental support for SS-RBD as a promising vaccine candidate due to its high secretion efficiency and preservation of neutralizing epitopes; and (3) a robust platform using PEA for high-sensitivity antigen characterization. This study enhances the fundamental understanding of spike protein biology and offers actionable insights for developing next-generation vaccines targeting SARS-CoV-2 and related coronaviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.